Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02302885 · ClinicalTrials.gov registry record
Healthy Human Control Blood Collection for Validation of Biomarker Assay
A clinical trial, sponsored by Abramson Cancer Center at Penn Medicine.
- Completed
- Registry status
- 43
- Enrollment target
NCT02302885: Completed study, sponsored by Abramson Cancer Center at Penn Medicine.
NCT02302885 is a clinical trial that has completed, run by Abramson Cancer Center at Penn Medicine. The registered enrollment target is 43 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02302885 has completed, sponsored by Abramson Cancer Center at Penn Medicine.
- COMPLETED
- Registry status
- 43 participants
- Enrollment target
Study Summary
Human blood will be collected to serve as control in validating clinical studies studying the detection and levels of circulating tumor cells and microvesicles in cancer patients. Targeted population is cancer-free 18-60 year old men and women. Volunteer selection will rely upon a short health questionnaire. About 20 mL blood will be collected from volunteers up to 20 different timepoints. The Procedure involves minimal risk of harm (eg discomfort, bruising) to the volunteer.
Interventions
- OTHER Blood collection
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 43 participants |
| Start Date | 2014-11 |
| Est. Completion | 2019-04-30 |
What the finished NCT02302885 record still lists
NCT02302885 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 43 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Blood collection is the first listed.
NCT02302885 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02302885 about?
NCT02302885 is a clinical study titled "Healthy Human Control Blood Collection for Validation of Biomarker Assay". Human blood will be collected to serve as control in validating clinical studies studying the detection and levels of circulating tumor cells and microvesicles in cancer patients. Targeted population is cancer-free 18-60 year old men and women. Volunteer selection will rely upon a short health quest...
What is the current status of trial NCT02302885?
This trial is currently completed. The enrollment target is 43 participants. The study started on 2014-11. Estimated completion is 2019-04-30.
What interventions are being tested in trial NCT02302885?
The interventions under investigation include: Blood collection (OTHER).
Who is sponsoring clinical trial NCT02302885?
This trial is sponsored by Abramson Cancer Center at Penn Medicine, which has 402 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03726359 · 43 participants · Phase 1
Phase I Study of Fractionated Stereotactic Radiation Therapy
- NCT03850418 · 43 participants · Phase 2
Azacitidine and Chimerism in MDS or AML Patients After Allogeneic Stem Cell Transplant
- NCT04144023 · 43 participants · Phase 1
A Vaccine (H2NVAC) Before Surgery for the Treatment of HER2-Expressing Ductal Carcinoma In Situ
- NCT04176718 · 43 participants · Phase 2
Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia